![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
InMed Pharmaceuticals Inc | NASDAQ:INM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0075 | -2.60% | 0.281 | 0.275 | 0.28 | 81,527 | 12:53:10 |
Director | Votes For | Withheld Votes | |||||
Number | Percentage | Number | Percentage | ||||
Eric A. Adams | 159,223 | 94.90 | % | 8,559 | 5.10 | % | |
Andrew Hull | 158,282 | 94.34 | % | 9,500 | 5.66 | % | |
Janet Grove | 162,246 | 96.70 | % | 5,536 | 3.30 | % | |
Bryan Baldasare | 160,764 | 95.82 | % | 7,018 | 4.18 | % | |
Nicole Lemerond | 162,174 | 96.66 | % | 5,608 | 3.34 | % |
InMed filed a report of voting results on SEDAR at www.sedar.com on December 15, 2022.
About InMed: InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com.
Investor Contact: Colin ClancyVice President, Investor RelationsT: +1.604.416.0999E: cclancy@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: being a global leader in the manufacturing and development of rare cannabinoids and delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
1 Year InMed Pharmaceuticals Chart |
1 Month InMed Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions